TPO Labs: When to Order and What Results Mean

Thyroid peroxidase (TPO) antibody testing is a single blood draw that measures antibodies directed against thyroid peroxidase, the enzyme thyroid cells use to make thyroid hormone. A result above the assay's cutoff, commonly cited as roughly 34 IU/mL on some platforms though the exact reference range depends on the laboratory and instrument used, indicates ongoing autoimmune activity against the thyroid gland. TPOAb is the most sensitive single serologic marker of Hashimoto thyroiditis, and its main clinical value is in explaining an abnormal TSH and in estimating the likelihood that mild thyroid dysfunction will worsen over time, not in monitoring disease activity once the diagnosis is already established.

What thyroid peroxidase antibodies are and why they matter

Thyroid peroxidase is an enzyme on the surface of thyroid follicular cells that is required for two steps in thyroid hormone synthesis: iodination of thyroglobulin and the coupling reaction that forms T3 and T4. When the immune system generates antibodies against this enzyme, the antibodies can activate complement and contribute to lymphocytic infiltration and gradual destruction of thyroid tissue. That means TPOAb is not just a diagnostic marker; it plausibly participates in the disease process itself, which is part of why its presence carries prognostic weight even when TSH is still normal.

Population surveys conducted in the United States in the 1990s (NHANES III) found TPOAb positivity in roughly one in ten adults without known thyroid disease, with higher rates in women and in older age groups. These figures are widely cited in endocrinology literature; readers who need the exact prevalence for a clinical or academic purpose should verify against the original NHANES III publication rather than relying on secondary citations, since the specific PMID commonly attached to this claim across the web is inconsistent.

When ordering TPO antibodies is likely to change management

An abnormal TSH with no known cause. This is the most common and best-supported indication. A positive TPOAb result in a patient with elevated TSH confirms autoimmune (Hashimoto) thyroiditis as the likely cause and generally ends the need for further etiologic workup. This is consistent with joint American Association of Clinical Endocrinologists and American Thyroid Association guidance on the evaluation of hypothyroidism.

Subclinical hypothyroidism (TSH modestly elevated, free T4 normal). Whether to start levothyroxine in this group is genuinely debated, and TPOAb status is one input into that decision. Long-running cohort data (the Whickham Survey and its follow-ups) are widely cited as showing that TPOAb-positive individuals with elevated TSH progress to overt hypothyroidism at a meaningfully higher annual rate than TPOAb-negative individuals with the same TSH. The precise percentages attached to this finding vary across secondary sources; a clinician relying on an exact annual conversion rate should confirm the number against the original cohort publication rather than a lab-test explainer.

Goiter or a thyroid nodule without an obvious cause. A diffusely enlarged gland with positive TPOAb points toward Hashimoto thyroiditis rather than iodine deficiency or an infiltrative process, and can reduce the need for further imaging-based etiologic workup in straightforward cases.

Recurrent pregnancy loss or infertility evaluation. Thyroid autoimmunity has been studied as a factor in unexplained recurrent spontaneous abortion. A 2024 retrospective study of pre-pregnancy testing in women with unexplained recurrent spontaneous abortion examined TPOAb along with other pre-pregnancy markers for their predictive value (Zhang et al., 2024). This is observational, retrospective evidence in a specific population (women already being evaluated for unexplained recurrent loss), and it supports considering TPOAb as one factor in that specific workup rather than as a general fertility screening test for all women trying to conceive.

Before therapies known to provoke thyroid autoimmunity. Amiodarone, lithium, and immune checkpoint inhibitors can unmask or worsen thyroid autoimmune disease. A baseline TPOAb, obtained before starting these drugs, can help a clinician anticipate which patients are more likely to develop drug-associated thyroid dysfunction, though monitoring TSH periodically during therapy remains the more actionable step regardless of baseline antibody status.

Pregnancy-specific indications. Professional guidelines from the American Thyroid Association recommend measuring TPOAb in pregnant patients with a TSH above the trimester-specific reference range, a personal history of thyroid disease, or a history of recurrent miscarriage. TPOAb positivity in early pregnancy is also associated with a substantially higher risk of postpartum thyroiditis than TPOAb-negative status, which supports closer postpartum TSH monitoring in antibody-positive patients.

When ordering TPO antibodies is unlikely to help

Repeat testing after Hashimoto thyroiditis is already diagnosed. Antibody titers fluctuate for reasons that are not fully understood, and tracking TPOAb over time does not change how levothyroxine dose is adjusted. TSH is the test that guides dose titration; TPOAb generally does not need to be rechecked once the autoimmune diagnosis is established.

Population-level or routine wellness screening in asymptomatic adults with normal TSH. General thyroid-disease screening in asymptomatic, nonpregnant adults is not supported by strong evidence at a population level, and adding TPOAb testing on top of a normal TSH in someone with no symptoms or risk factors usually generates anxiety and follow-up testing without a clear benefit.

When the cause of hypothyroidism is already known. A patient with hypothyroidism from prior radioiodine ablation or thyroid surgery does not need TPOAb to confirm an autoimmune cause, because the cause is already established by history.

Decision framework: should this patient get a TPO antibody test?

What counts as a normal or abnormal result

Most commercial immunoassays report a negative result somewhere in the range of single digits to the mid-30s in IU/mL, and different laboratories and instrument platforms use different cutoffs. A description of how clinical laboratories implement thyroid-function-test algorithms, including reflex antibody testing and platform-specific reference intervals, is discussed in an analysis of laboratory practice in a tertiary hospital setting (Anastasopoulou et al., 2018). The practical takeaway is that a TPOAb value only means something in relation to the reference range printed by the reporting lab, not a single number that applies everywhere.

Higher titers are generally understood to reflect more active autoimmune destruction, and some longitudinal data suggest a higher titer at baseline is associated with a greater likelihood of progressing to overt hypothyroidism. Exact progression percentages tied to specific titer cutoffs (for example, above versus below 500 IU/mL) appear in the literature but vary between studies and populations; treat any single precise percentage you encounter for this comparison as something to verify against the original study before using it for individual counseling.

What a positive result means, and what it does not mean

A positive TPOAb result means an autoimmune process against the thyroid is active. It is most commonly associated with Hashimoto thyroiditis, where it is detected in the large majority of confirmed cases, but it is not specific to Hashimoto disease. It can also appear in Graves disease, type 1 diabetes, and other autoimmune conditions.

A positive result in a patient whose thyroid function is still normal (euthyroid) is not meaningless. It indicates ongoing autoimmune activity even while the gland is still compensating, and cohort data consistently show a higher rate of progression to hypothyroidism in TPOAb-positive euthyroid people compared with antibody-negative people, even if the exact annual percentage varies across studies. A reasonable practical response to a positive result in an otherwise euthyroid patient is a repeat TSH and free T4, a thyroid exam, and an annual TSH recheck going forward rather than immediate treatment.

What a negative result means, and what it does not mean

A negative result makes an autoimmune process less likely but does not rule it out. A meaningful minority of people with biopsy-confirmed Hashimoto thyroiditis test negative for TPOAb; in that situation thyroglobulin antibodies (TgAb) may be the only positive marker, and TgAb testing is a reasonable second step when clinical suspicion (goiter, characteristic ultrasound pattern, abnormal TSH) remains high despite a negative TPOAb.

A negative TPOAb in someone with subclinical hypothyyroidism is reassuring and can support a watch-and-recheck approach rather than starting treatment right away. A negative TPOAb in someone with overt hyperthyroidism shifts the differential away from Graves disease toward other causes such as toxic nodular disease or thyroiditis, and TSH receptor antibodies (TRAb), not TPOAb, become the more informative test in that scenario.

Interpreting TPOAb together with TSH and free T4

TPOAb does not carry diagnostic meaning on its own. It has to be read alongside TSH and free T4.

• TSH elevated, free T4 low, TPOAb positive: consistent with Hashimoto thyroiditis; levothyroxine is typically indicated.
• TSH mildly elevated, free T4 normal, TPOAb positive: subclinical hypothyroidism with an autoimmune basis; consider treatment, or monitor TSH every 6 to 12 months if deferring.
• TSH mildly elevated, free T4 normal, TPOAb negative: consider that the TSH elevation may be transient before committing to treatment; a short-interval recheck (a few weeks) is often reasonable.
• TSH normal, free T4 normal, TPOAb positive: euthyroid autoimmune thyroiditis; annual TSH monitoring is a reasonable baseline plan.

One reason a single TSH value can be misleading on its own is that TSH has substantial biological within-person variability across the day and across weeks, separate from any true change in thyroid status. This variability is discussed in detail in a review of within-person TSH variation and its clinical implications (Ehrenkranz et al., 2021). Practically, this supports confirming a borderline TSH before making a treatment decision, and it is part of why guidelines favor a single confirmed TPOAb result over repeated titer-chasing: TSH trend matters more than antibody trend for day-to-day management.

Can TPO antibody levels be lowered, and does it matter?

Several interventions have shown some reduction in TPOAb titers in controlled or observational studies. None of them have been clearly shown to prevent progression to hypothyroidism based on the antibody reduction alone, and that distinction matters for how a patient should weigh these options.

• Selenium supplementation. Selenium (commonly studied at 200 mcg/day of sodium selenite) has been studied in randomized trials in people with Hashimoto thyroiditis and has been reported to lower TPOAb titers over several months of use. Whether this translates into fewer people needing levothyroxine, or into any change in clinical symptoms, has not been clearly established, and selenium supplementation carries its own risks at higher doses. Anyone considering this should discuss it with their clinician rather than self-dosing, particularly given the narrow margin between adequate and excessive selenium intake.
• Levothyroxine therapy. In patients who are already hypothyroid, correcting TSH with levothyroxine has been observed to reduce antibody titers over one to two years in some studies, though titers rarely normalize completely, and levothyroxine is not started for the purpose of lowering antibodies; it is started to correct hormone deficiency.
• Vitamin D repletion. Observational studies show an inverse association between vitamin D levels and TPOAb titers, but this is correlational, and interventional trials of vitamin D supplementation for this purpose have produced inconsistent results. Correcting a genuine vitamin D deficiency is reasonable for general health reasons, not because it is a proven thyroid-specific treatment.
• Gluten-free diet. Celiac disease and autoimmune thyroid disease occur together more often than chance would predict, but no controlled trial demonstrates that a gluten-free diet lowers TPOAb in people who do not have celiac disease. This intervention should not be recommended on the basis of TPOAb alone without a celiac diagnosis.
• Myo-inositol. Small studies combining myo-inositol with selenium have reported greater antibody reduction than selenium alone, but sample sizes have been small and the finding needs replication before it can be treated as established practice.

TPO antibodies and pregnancy planning

Thyroid autoimmunity in pregnancy is treated with more urgency than in the general population because untreated or unmonitored thyroid dysfunction during pregnancy carries real risks to the pregnancy and to fetal neurodevelopment. Professional obstetric and endocrine guidelines recommend TPOAb testing in specific pregnant populations: those with an abnormal trimester-specific TSH, a personal history of thyroid disease, or a history of recurrent pregnancy loss.

TPOAb-positive pregnant patients, even when euthyroid at baseline, are at higher risk of developing overt hypothyroidism during pregnancy and of postpartum thyroiditis after delivery. This supports closer TSH monitoring through pregnancy and into the postpartum period in TPOAb-positive patients, generally with TSH checks at intervals such as three and six months postpartum, rather than a one-time test with no follow-up. Whether to start low-dose levothyroxine in a euthyroid, TPOAb-positive pregnant patient with a history of pregnancy loss is a decision that should be made with an obstetric or endocrine specialist, since trial evidence in this area is mixed and guideline recommendations have evolved over time; readers should confirm the current recommendation with their own obstetric team rather than relying on a general reference article.

What is established, what is plausible, and what is not established

Established: TPOAb is the most sensitive single serologic marker of Hashimoto thyroiditis and is useful for confirming an autoimmune cause of an abnormal TSH. A positive result in an otherwise euthyroid person is associated with a higher future risk of developing hypothyroidism than a negative result. Reference ranges vary meaningfully across laboratory platforms.

Plausible but not fully proven: That lowering TPOAb titers with selenium, levothyroxine, vitamin D, or myo-inositol changes long-term clinical outcomes such as need for thyroid hormone replacement, pregnancy outcomes, or symptom burden, independent of correcting TSH itself.

Not established: That TPOAb should be used as a general population screening test in asymptomatic adults with normal TSH, that serial TPOAb monitoring should guide levothyroxine dose adjustments, or that dietary interventions such as a gluten-free diet meaningfully lower TPOAb in people without celiac disease.

When to seek care sooner rather than wait for routine follow-up

A positive TPOAb result is not an emergency. However, symptoms such as a rapidly enlarging neck mass, difficulty swallowing or breathing, a racing heart with weight loss and tremor, or new symptoms of significant hypothyroidism (extreme fatigue, cold intolerance, swelling) alongside an abnormal thyroid panel warrant prompt evaluation rather than waiting for a scheduled follow-up appointment.